GNTbm

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) focuses on the field of new drug development, utilizing gold nanoparticles as a material to develop the core technology of the Vaucarrin® gold nanoparticle drug delivery platform, creating gold nanoparticle drugs for treating cancer and rheumatoid arthritis. On the other hand, in collaboration with international pharmaceutical companies, GNTbm is developing a new generation of epigenetic regulation-targeted drugs—chidamide—for the treatment of peripheral T-cell lymphoma, breast cancer, and multiple new cancer indications. Great Novel Therapeutics addresses unmet clinical needs by developing highly active and innovative nano-formulated drugs to meet patient demands.